FRM
SRNE

Fox Run Management’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Fox Run Management’s Portfolio SRNE Stock Details SRNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-14,701
Closed -$68K – 769
2021
Q4 		$68K Buy
+14,701
New +$91.3K 0.04% 434
2021
Q1 		– Sell
-13,638
Closed -$93K – 336
2020
Q4 		$93K Buy
+13,638
New +$110K 0.19% 178

Other funds holding SRNE

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Rafferty Asset Management
Rafferty Asset Management New York $43.9B AUM 121.74% 1-Year Est. Return

Fox Run Management's SRNE Position: Q1 2022 in Review

Fox Run Management sold out of Sorrento Therapeutics, Inc. (SRNE) in Q1 2022, closing a stake of 14,701 shares — an estimated $68K sold.

Fox Run Management first reported a position in SRNE in Q4 2020 and held it in 2 quarters. The position peaked at $93K in Q4 2020. 235 funds tracked by Wall St. Rank hold SRNE as of Q1 2022.

  • Fox Run Management reported no remaining Sorrento Therapeutics, Inc. position as of Q1 2022 after selling out during the quarter.
  • Fox Run Management sold 14,701 Sorrento Therapeutics, Inc. shares in Q1 2022, an estimated $68K.
  • Fox Run Management first reported a position in Sorrento Therapeutics, Inc. in Q4 2020 and held it in 2 quarters.
  • Fox Run Management's Sorrento Therapeutics, Inc. position peaked at $93K in Q4 2020.
  • 235 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q1 2022.

Based on Fox Run Management's 13F filing for Q1 2022, filed 10 May 2022.